Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke (TRUST)

NCT03519737 is registered in ClinicalTrials.gov with Cerevast Medical, Inc. as lead sponsor.

NCT NCT03519737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke (TRUST)
Lead sponsor
Cerevast Medical, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
August 17, 2018
Completion date
December 31, 2021
Enrollment
596 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke